1
|
Prieto-Potin I, Idrovo F, Suárez-Gauthier A, Díaz-Blázquez M, Astilleros-Blanco de Córdova L, Chamizo C, Zazo S, Carvajal N, López-Sánchez A, Pérez-Buira S, Aúz-Alexandre CL, Manso R, Plaza-Sánchez J, de Lucas-López V, Pérez-González N, Martín-Valle S, Cristóbal I, Casado V, García-Foncillas J, Rojo F. Comprehensive Approach to Genomic and Immune Profiling: Insights of a Real-World Experience in Gynecological Tumors. Diagnostics (Basel) 2022; 12:diagnostics12081903. [PMID: 36010253 PMCID: PMC9406465 DOI: 10.3390/diagnostics12081903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2022] [Revised: 07/22/2022] [Accepted: 08/03/2022] [Indexed: 11/25/2022] Open
Abstract
Gynecological cancer accounts for an elevated incidence worldwide requiring responsiveness regarding its care. The comprehensive genomic approach agrees with the classification of certain tumor types. We evaluated 49 patients with gynecological tumors undergoing high-throughput sequencing to explore whether identifying alterations in cancer-associated genes could characterize concrete histological subtypes. We performed immune examination and analyzed subsequent clinical impact. We found 220 genomic aberrations mostly distributed as single nucleotide variants (SNV, 77%). Only 3% were classified as variants of strong clinical significance in BRCA1 and BRCA2 of ovarian high-grade serous (HGSC) and uterine endometrioid carcinoma. TP53 and BRCA1 occurred in 72% and 28% of HGSC. Cervical squamous cell carcinoma was entirely HPV-associated and mutations occurred in PIK3CA (60%), as well as in uterine serous carcinoma (80%). Alterations were seen in PTEN (71%) and PIK3CA (60%) of uterine endometrioid carcinoma. Elevated programmed death-ligand 1 (PD-L1) was associated with high TILs. Either PD-L1 augmented in deficient mis-matched repair (MMR) proteins or POLE mutated cases when compared to a proficient MMR state. An 18% received genotype-guided therapy and a 4% immunotherapy. The description of tumor subtypes is plausible through high-throughput sequencing by recognizing clinically relevant alterations. Additional concomitant assessment of immune biomarkers identifies candidates for immunotherapy.
Collapse
Affiliation(s)
- Iván Prieto-Potin
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Franklin Idrovo
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Ana Suárez-Gauthier
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - María Díaz-Blázquez
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | | | - Cristina Chamizo
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Sandra Zazo
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Nerea Carvajal
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Almudena López-Sánchez
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Sandra Pérez-Buira
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Carmen Laura Aúz-Alexandre
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Rebeca Manso
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Jenifer Plaza-Sánchez
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Virginia de Lucas-López
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Nuria Pérez-González
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Sara Martín-Valle
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Ion Cristóbal
- Cancer Unit for Research on Novel Therapeutic Targets, Oncohealth Institute, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
- Translational Oncology Division, Oncohealth Institute, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Victoria Casado
- Translational Oncology Division, Oncohealth Institute, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Jesús García-Foncillas
- Cancer Unit for Research on Novel Therapeutic Targets, Oncohealth Institute, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
- Translational Oncology Division, Oncohealth Institute, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
| | - Federico Rojo
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, 28040 Madrid, Spain
- Correspondence:
| |
Collapse
|
2
|
Rodríguez‐Pinilla SM, Salgado RN, Chamizo C, Santonja C, Stewart P, Carvajal N, McCafferty N, Manso R, Morillo D, Piris MÁ, González de Castro D. Redefining the high‐grade B cell lymphoma with double/triple rearrangements of MYC and BCL2/BCL6 genes. Learning from a case report. eJHaem 2022; 3:171-174. [PMID: 35846201 PMCID: PMC9175839 DOI: 10.1002/jha2.310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/28/2021] [Revised: 09/14/2021] [Accepted: 09/20/2021] [Indexed: 11/05/2022]
Abstract
We report a patient initially diagnosed with a triple hit high‐grade B cell lymphoma (HGBL‐TH), in which further morphologic, immunohistochemical, and next‐generation sequencing studies of subsequent specimens disclosed it to be a germinal center diffuse large B cell lymphoma (GC‐DLBCL) with BCL2/BCL6 gene translocations, PVT1‐deletion, and gain of MYC genes evolving from a previous follicular lymphoma. However, fluorescence in situ hybridization (FISH) studies with the break‐apart probe for MYC gene showed a fusion and two separated signals (red and green, respectively) leading to the interpretation of MYC gene translocation and a false diagnosis of a TH‐lymphoma, according to the recent WHO classification. Nevertheless, PVT1 deletion plus MYC gain/amplification has been described as a cause of the double‐hi transcription profile. These data highlight the need for new criteria to identify these highly aggressive lymphomas.
Collapse
Affiliation(s)
| | - Rocío Nieves Salgado
- Cytogenetic Department Hospital Universitario Fundación Jiménez Díaz (FJD) Madrid Spain
| | - Cristina Chamizo
- Pathology Department Hospital Universitario Fundación Jiménez Díaz (FJD) Madrid Spain
| | - Carlos Santonja
- Pathology Department Hospital Universitario Fundación Jiménez Díaz (FJD) Madrid Spain
| | - Peter Stewart
- Patrick G Johnston Centre for Cancer Research Queen's University Belfast Belfast UK
| | - Nerea Carvajal
- Pathology Department Hospital Universitario Fundación Jiménez Díaz (FJD) Madrid Spain
| | - Neil McCafferty
- Patrick G Johnston Centre for Cancer Research Queen's University Belfast Belfast UK
| | - Rebeca Manso
- Pathology Department Hospital Universitario Fundación Jiménez Díaz (FJD) Madrid Spain
| | - Daniel Morillo
- Haematology Department Hospital Universitario Fundación Jiménez Díaz Madrid Spain
| | - Miguel Ángel Piris
- Pathology Department Hospital Universitario Fundación Jiménez Díaz (FJD) Madrid Spain
| | | |
Collapse
|
3
|
Manso R, Rodriguez M, Chamizo C, Pérez N, Alonso‐Alonso R, Minguez PA, Borregon J, Baez‐Duran E, Casas‐del Pozo EM, Piris MA, Rojo F, Rodriguez‐Pinilla SM. INTESTINAL T‐CELL LYMPHOMAS: MOLECULAR INTEGRATIVE ANALYSIS RECOGNIZES DIFFERENT THERAPEUTIC TARGETS FOR EACH SUBTYPE. Hematol Oncol 2021. [DOI: 10.1002/hon.13_2881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- R Manso
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | - M Rodriguez
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | - C Chamizo
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | - N Pérez
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | | | - P. A Minguez
- Fundacion Jimenez Diaz Genetics and Genomics Department and Bioinformatics Unit Madrid Spain
| | - J Borregon
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | | | | | - M. A Piris
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | - F Rojo
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | | |
Collapse
|
4
|
Machan S, Rodriguez M, Manso R, Borregon J, Chamizo C, Alonso‐Alonso R, Pérez Buira S, Rodríguez‐Peralto JL, Cerroni L, Cereceda L, Córdoba R, Án. Piris M, Requena L, María Rodríguez‐Pinilla S. SUBCUTANEOUS PANNICULITIS‐LIKE T‐CELL LYMPHOMA: MOLECULAR AND MUTATIONAL CHARACTERIZATION COMPARED WITH LUPUS PANNICULITIS AND HISTOPATHOLOGIC OVERLAPPING CASES. Hematol Oncol 2021. [DOI: 10.1002/hon.138_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- S Machan
- Fundación Jiménez Díaz‐Universidad Autónoma de Madrid, Dermatology Madrid Spain
| | - M Rodriguez
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | - R Manso
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | - J Borregon
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | - C Chamizo
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | | | | | | | - L Cerroni
- Medical University of Graz, Dermatology Graz Austria
| | - L Cereceda
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | - R Córdoba
- Fundación Jiménez Díaz, Hematology Madrid Spain
| | - M Án. Piris
- Fundación Jiménez Díaz, Pathology Madrid Spain
| | - L Requena
- Fundación Jiménez Díaz‐Universidad Autónoma de Madrid, Dermatology Madrid Spain
| | | |
Collapse
|
5
|
Prieto-Potin I, Carvajal N, Plaza-Sánchez J, Manso R, Aúz-Alexandre CL, Chamizo C, Zazo S, López-Sánchez A, Rodríguez-Pinilla SM, Camacho L, Longarón R, Bellosillo B, Somoza R, Hernández-Losa J, Fernández-Soria VM, Ramos-Ruiz R, Cristóbal I, García-Foncillas J, Rojo F. Validation and clinical application of a targeted next-generation sequencing gene panel for solid and hematologic malignancies. PeerJ 2020; 8:e10069. [PMID: 33083132 PMCID: PMC7546223 DOI: 10.7717/peerj.10069] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Accepted: 09/09/2020] [Indexed: 01/29/2023] Open
Abstract
Background Next-generation sequencing (NGS) is a high-throughput technology that has become widely integrated in molecular diagnostics laboratories. Among the large diversity of NGS-based panels, the Trusight Tumor 26 (TsT26) enables the detection of low-frequency variants across 26 genes using the MiSeq platform. Methods We describe the inter-laboratory validation and subsequent clinical application of the panel in 399 patients presenting a range of tumor types, including gastrointestinal (GI, 29%), hematologic (18%), lung (13%), gynecological and breast (8% each), among others. Results The panel is highly accurate with a test sensitivity of 92%, and demonstrated high specificity and positive predictive values (95% and 96%, respectively). Sequencing testing was successful in two-thirds of patients, while the remaining third failed due to unsuccessful quality-control filtering. Most detected variants were observed in the TP53 (28%), KRAS (16%), APC (10%) and PIK3CA (8%) genes. Overall, 372 variants were identified, primarily distributed as missense (81%), stop gain (9%) and frameshift (7%) altered sequences and mostly reported as pathogenic (78%) and variants of uncertain significance (19%). Only 14% of patients received targeted treatment based on the variant determined by the panel. The variants most frequently observed in GI and lung tumors were: KRAS c.35G > A (p.G12D), c.35G > T (p.G12V) and c.34G > T (p.G12C). Conclusions Prior panel validation allowed its use in the laboratory daily practice by providing several relevant and potentially targetable variants across multiple tumors. However, this study is limited by high sample inadequacy rate, raising doubts as to continuity in the clinical setting.
Collapse
Affiliation(s)
- Iván Prieto-Potin
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| | - Nerea Carvajal
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| | - Jenifer Plaza-Sánchez
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| | - Rebeca Manso
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| | - Carmen Laura Aúz-Alexandre
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| | - Cristina Chamizo
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| | - Sandra Zazo
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| | - Almudena López-Sánchez
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| | | | - Laura Camacho
- Department of Pathology, Hospital Del Mar Medical Research Institute, Barcelona, Spain
| | - Raquel Longarón
- Department of Pathology, Hospital Del Mar Medical Research Institute, Barcelona, Spain
| | - Beatriz Bellosillo
- Department of Pathology, Hospital Del Mar Medical Research Institute, Barcelona, Spain
| | - Rosa Somoza
- Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain
| | | | | | | | - Ion Cristóbal
- Translational Oncology Division, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| | - Jesús García-Foncillas
- Translational Oncology Division, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| | - Federico Rojo
- Department of Pathology, CIBERONC, UAM, Fundación Jiménez Díaz University Hospital Health Research Institute, Madrid, Spain
| |
Collapse
|
6
|
Zazo S, González-Alonso P, Martín-Aparicio E, Chamizo C, Luque M, Sanz-Álvarez M, Mínguez P, Gómez-López G, Cristóbal I, Caramés C, García-Foncillas J, Eroles P, Lluch A, Arpí O, Rovira A, Albanell J, Madoz-Gúrpide J, Rojo F. Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer. Mol Cancer Ther 2020; 19:1696-1707. [PMID: 32404410 DOI: 10.1158/1535-7163.mct-19-1172] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2019] [Revised: 03/26/2020] [Accepted: 05/07/2020] [Indexed: 11/16/2022]
Abstract
HER2-positive breast cancer is currently managed with chemotherapy in combination with specific anti-HER2 therapies, including trastuzumab. However, a high percentage of patients with HER2-positive tumors do not respond to trastuzumab (primary resistance) or either recur (acquired resistance), mostly due to molecular alterations in the tumor that are either unknown or undetermined in clinical practice. Those alterations may cause the tumor to be refractory to treatment with trastuzumab, promoting tumor proliferation and metastasis. Using continued exposure of a HER2-positive cell line to trastuzumab, we generated a model of acquired resistance characterized by increased expression of several cytokines. Differential gene expression analysis indicated an overexpression of 15 genes, including five different chemokines, and highlighting CCL5/RANTES as the most overexpressed one. Functional studies, either by in vitro gene silencing or by in vitro and in vivo pharmacologic inhibition of the CCL5/CCR5 interaction with maraviroc, confirmed that CCL5 overexpression was implicated in acquired resistance to trastuzumab, which was mediated by ERK activation. In patient samples, increased CCL5 expression significantly correlated with lower rates of complete response after neoadjuvant therapy, confirmed by detection of high serum CCL5 levels by ELISA. Overexpression of CCL5 correlated with ERK phosphorylation in tumor cells and was statistically associated with worse disease-free survival and overall cancer survival in patients with early HER2-positive breast cancer.
Collapse
Affiliation(s)
- Sandra Zazo
- Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS-FJD, UAM)-CIBERONC, Madrid, Spain
| | - Paula González-Alonso
- Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS-FJD, UAM)-CIBERONC, Madrid, Spain
| | - Ester Martín-Aparicio
- Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS-FJD, UAM)-CIBERONC, Madrid, Spain
| | - Cristina Chamizo
- Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS-FJD, UAM)-CIBERONC, Madrid, Spain
| | - Melani Luque
- Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS-FJD, UAM)-CIBERONC, Madrid, Spain
| | - Marta Sanz-Álvarez
- Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS-FJD, UAM)-CIBERONC, Madrid, Spain
| | - Pablo Mínguez
- Department of Genetics, Health Research Institute-Fundación Jiménez Díaz (IIS-FJD, UAM), Center for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, Madrid, Spain
| | - Gonzalo Gómez-López
- Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Ion Cristóbal
- Translational Oncology Division, OncoHealth Institute, Health Research Institute-Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain
| | - Cristina Caramés
- Translational Oncology Division, OncoHealth Institute, Health Research Institute-Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain
| | - Jesús García-Foncillas
- Translational Oncology Division, OncoHealth Institute, Health Research Institute-Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain
| | - Pilar Eroles
- Institute of Health Research INCLIVA-CIBERONC, Valencia, Spain
| | - Ana Lluch
- Institute of Health Research INCLIVA-CIBERONC, Valencia, Spain.,Department of Medicine, University of Valencia, Valencia, Spain
| | - Oriol Arpí
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain
| | - Ana Rovira
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.,Department of Medical Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain
| | - Joan Albanell
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.,Department of Medical Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain.,Universitat Pompeu Fabra, Barcelona, Spain
| | - Juan Madoz-Gúrpide
- Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS-FJD, UAM)-CIBERONC, Madrid, Spain.
| | - Federico Rojo
- Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS-FJD, UAM)-CIBERONC, Madrid, Spain.
| |
Collapse
|
7
|
González-Alonso P, Zazo S, Martín-Aparicio E, Luque M, Chamizo C, Sanz-Álvarez M, Minguez P, Gómez-López G, Cristóbal I, Caramés C, García-Foncillas J, Eroles P, Lluch A, Arpí O, Rovira A, Albanell J, Piersma SR, Jimenez CR, Madoz-Gúrpide J, Rojo F. The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer. Cancers (Basel) 2020; 12:cancers12051108. [PMID: 32365528 PMCID: PMC7281325 DOI: 10.3390/cancers12051108] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2020] [Revised: 04/26/2020] [Accepted: 04/27/2020] [Indexed: 12/19/2022] Open
Abstract
Trastuzumab is the first-line targeted therapeutic drug for HER2-positive breast cancer, leading to improved overall survival. However, acquired resistance inevitably occurs. We aimed to identify, quantify, and assess the mechanisms of acquired resistance to trastuzumab. We established an acquired trastuzumab-resistant model in vitro from BT-474, a trastuzumab-sensitive, HER2-amplified breast-cancer cell line. A multi-omic strategy was implemented to obtain gene, proteome, and phosphoproteome signatures associated with acquired resistance to trastuzumab in HER2-positive breast cancer, followed by validation in human clinical samples. YAP1 dephosphorylation and TEAD2 overexpression were detected as significant alterations in the Hippo pathway in trastuzumab-resistant breast cancer. Because of the emerging role of these proteins as mediators of normal growth and tumorigenesis, we assessed the exogenous modulation of their activity, either by in vitro gene silencing or by pharmacological inhibition of the YAP1/TEAD complexes, both in vitro and in vivo. Moreover, we identified increased signaling through the Hippo pathway in human samples after progression following trastuzumab treatment. Finally, YAP1/TAZ nuclear accumulation in malignant cells in HER2 breast tumor was significantly associated with worse progression-free and overall survival in metastatic HER2-positive breast-cancer patients. Our results suggest the involvement of Hippo signaling in acquired trastuzumab resistance in breast cancer. Additionally, we provide novel evidence for a potential breast-cancer treatment strategy based on dual targeting of HER2 and Hippo pathway effectors, which may improve the antitumor activity of trastuzumab and help overcome resistance.
Collapse
Affiliation(s)
- Paula González-Alonso
- Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS—FJD, UAM)—CIBERONC, 28040 Madrid, Spain
| | - Sandra Zazo
- Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS—FJD, UAM)—CIBERONC, 28040 Madrid, Spain
| | - Ester Martín-Aparicio
- Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS—FJD, UAM)—CIBERONC, 28040 Madrid, Spain
| | - Melani Luque
- Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS—FJD, UAM)—CIBERONC, 28040 Madrid, Spain
| | - Cristina Chamizo
- Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS—FJD, UAM)—CIBERONC, 28040 Madrid, Spain
| | - Marta Sanz-Álvarez
- Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS—FJD, UAM)—CIBERONC, 28040 Madrid, Spain
| | - Pablo Minguez
- Genetics Department, Health Research Institute-Fundación Jiménez Díaz (IIS-FJD, UAM), Center for Biomedical Network Research on Rare Diseases (CIBERER), ISCIII, 28040 Madrid, Spain
| | - Gonzalo Gómez-López
- Bioinformatics Unit, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain
| | - Ion Cristóbal
- Translational Oncology Division, OncoHealth Institute, Health Research Institute-Fundación Jiménez Díaz (IIS-FJD, UAM), 28040 Madrid, Spain
| | - Cristina Caramés
- Translational Oncology Division, OncoHealth Institute, Health Research Institute-Fundación Jiménez Díaz (IIS-FJD, UAM), 28040 Madrid, Spain
| | - Jesús García-Foncillas
- Translational Oncology Division, OncoHealth Institute, Health Research Institute-Fundación Jiménez Díaz (IIS-FJD, UAM), 28040 Madrid, Spain
| | - Pilar Eroles
- Institute of Health Research INCLIVA-CIBERONC, 46010 Valencia, Spain
| | - Ana Lluch
- Institute of Health Research INCLIVA-CIBERONC, 46010 Valencia, Spain
| | - Oriol Arpí
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), 08003 Barcelona, Spain
| | - Ana Rovira
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), 08003 Barcelona, Spain
- Medical Oncology Department, Hospital del Mar-CIBERONC, 08003 Barcelona, Spain
| | - Joan Albanell
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), 08003 Barcelona, Spain
- Medical Oncology Department, Hospital del Mar-CIBERONC, 08003 Barcelona, Spain
- CEXS Department, Pompeu Fabra University, 08002 Barcelona, Spain
| | - Sander R. Piersma
- OncoProteomics Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Center (location VUmc), 1081 HV Amsterdam, The Netherlands
| | - Connie R. Jimenez
- OncoProteomics Laboratory, Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam University Medical Center (location VUmc), 1081 HV Amsterdam, The Netherlands
| | - Juan Madoz-Gúrpide
- Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS—FJD, UAM)—CIBERONC, 28040 Madrid, Spain
- Correspondence: (J.M.-G.); (F.R.); Tel.: +34-915-504-800 (J.M.-G.); +34-915-504-800 (F.R.)
| | - Federico Rojo
- Pathology, Fundación Jiménez Díaz University Hospital Health Research Institute (IIS—FJD, UAM)—CIBERONC, 28040 Madrid, Spain
- Correspondence: (J.M.-G.); (F.R.); Tel.: +34-915-504-800 (J.M.-G.); +34-915-504-800 (F.R.)
| |
Collapse
|
8
|
Hernandez-Guerrero T, Pedregal M, Rubio J, Ruiz-Hispán E, Fernandez M, Martinez I, Doger B, Lage Alfranca Y, Ruperez AB, Zenzola V, Casado V, Martin-Valades JI, Carvajal N, Chamizo C, Domine M, García Foncillas J, Moreno V. DNA repair pathway alterations and correlation with immunotherapy response. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.e14150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e14150 Background: Over the past decade, a better understanding of cancer biology has led to a revolution in immunotherapy. Checkpoint inhibitors (ICI), bispecific antibodies and agonistic agents have shown benefit in cancer treatment. Unfortunately, not all patients benefit and, despite the advances achieved in discovering markers of response, the selection of patients can still be challenging in everyday practice. Methods: We conducted a retrospective analysis of potential prognostic and predictive factors of survival in a cohort of 186 patients enrolled into Phase I Trials testing immunotherapeutic agents at our institution. We computed univariate and multivariate analysis (MVA) of demographics, clinical and molecular characteristics to assess their prognostic and predictive potential of clinical benefit (defined as achieving Complete or Partial Response (CR/PR) as best response or disease stabilization lasting > 120 days) and survival. Molecular testing included Next Generation Sequencing (NGS - Oncomine Comprehensive Assay) grouped in DNA repair, Transcription regulation, Signal Transduction and Cell-Cell interaction pathways. Results: A total of 186 patients (Male/Female: 81/105; median age 61yo) received treatment with either immune checkpoint inhibitors (122 (65,6%)), checkpoint agonists (37 (19.9%)); bispecific antibodies (19 (10.21%) or other immunotherapies (8 (4.29%)) between November 2015 and July 2018. Royal Marsden Score (RMH) was assessed and correlated with progression free survival and overall survival in the total cohort. Median Overall Survival (mOS) was 422 days (CI95%: 345-500 days), 387 (CI95%: 297-478 days), 235 (CI95%: 131-338 days), and 167 (CI95% 64-270 days) for RMH 0, 1, 2 and 3, respectively (p = 0.007). Among 57 patients with NGS results, those with pathogenic mutations in DNA repair pathways (n = 26) showed a trend towards a higher response rate (69% vs 30% p = 0.064) and clinical benefit (65% vs 35%; p = 0.034). Conclusions: Alterations in DNA repair pathways are a potential predictor of benefit of immunotherapy and warrants further studies. A larger cohort of patients is currently being explored in our center to further validate these findings.
Collapse
Affiliation(s)
| | | | - Jaime Rubio
- Fundacion Jimenez Diaz University Hospital, Madrid, Spain
| | | | | | | | | | | | | | - Victor Zenzola
- Fundacion Jimenez Diaz University Hospital, Madrid, Spain
| | - Victoria Casado
- Oncology Department. Hospital Universitario. Fundacion Jimenez Diaz, Madrid, Spain
| | - Jose Ignacio Martin-Valades
- Oncology Department and Translational Oncology Division, University Hospital Fundacion Jimenez Diaz, Madrid, Spain
| | - Nerea Carvajal
- Translational Oncology Division. Hospital Universitario. Fundacion Jimenez Diaz, Madrid, Spain
| | - Cristina Chamizo
- Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Manuel Domine
- Oncology Department and Translational Oncology Division, University Hospital Fundacion Jimenez Diaz, Madrid, Spain
| | | | | |
Collapse
|
9
|
Torrejón B, Cristóbal I, Caramés C, Prieto-Potín I, Chamizo C, Santos A, Sanz-Alvarez M, Serna-Blasco R, Luque M, Madoz-Gúrpide J, Rojo F, García-Foncillas J. Analysis of Potential Alterations Affecting SETBP1 as a Novel Contributing Mechanism to Inhibit PP2A in Colorectal Cancer Patients. World J Surg 2018; 42:3771-3778. [PMID: 29796729 DOI: 10.1007/s00268-018-4684-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND The functional loss of the tumor suppressor protein phosphatase 2A (PP2A) occurs in a wide variety of human cancers including colorectal cancer (CRC), and SET overexpression has been reported as a key contributing mechanism to inhibit PP2A. Although SET binding protein 1 (SETBP1) overexpression and gain of function mutations have been described in several hematological malignancies as common events that increase the expression levels of the PP2A inhibitor SET, thereby leading to PP2A inactivation, the potential existence of SETBP1 alterations in CRC still remains unexplored. METHODS We studied the expression profile of SETBP1 by Western blot in a set of CRC cell lines and patient samples. Moreover, we performed co-immunoprecipitation assays to analyze the formation of the previously reported SETBP1-SET-PP2A inhibitory complex. Furthermore, we evaluated the mutational status of SETBP1 by pyrosequencing assays in a cohort of 55 CRC patients with metastatic disease after the immunohistochemical characterization of SET and p-PP2A expression in this cohort. RESULTS We found high SETBP1 expression in several CRC lines but only in two of the patients analyzed. In addition, we demonstrated the formation of the SETBP1-SET-PP2A heterotrimeric complex in CRC cells. However, we failed to detect SETBP1 mutations in any of the CRC patient samples included in the study. CONCLUSIONS Our results suggest that SETBP1 expression is mainly similar o lower in colorectal cancer tissue compared to normal colonic mucosa. However, its overexpression is a low prevalent alteration which could contribute to inhibit PP2A in CRC through the formation of a SETBP1-SET-PP2A complex in some CRC patients. Moreover, SETBP1 mutations are, if exist, rare events in CRC patients.
Collapse
Affiliation(s)
- Blanca Torrejón
- Translational Oncology Division, Oncohealth Institute, IIS-Fundación Jiménez Diaz, Autonomous University of Madrid, University Hospital "Fundación Jiménez Diaz", Avda. Reyes Católicos-2, 28040, Madrid, Spain
| | - Ion Cristóbal
- Translational Oncology Division, Oncohealth Institute, IIS-Fundación Jiménez Diaz, Autonomous University of Madrid, University Hospital "Fundación Jiménez Diaz", Avda. Reyes Católicos-2, 28040, Madrid, Spain.
| | - Cristina Caramés
- Translational Oncology Division, Oncohealth Institute, IIS-Fundación Jiménez Diaz, Autonomous University of Madrid, University Hospital "Fundación Jiménez Diaz", Avda. Reyes Católicos-2, 28040, Madrid, Spain
| | - Iván Prieto-Potín
- Pathology Department, Autonomous University of Madrid, University Hospital "Fundación Jiménez Diaz", 28040, Madrid, Spain
| | - Cristina Chamizo
- Translational Oncology Division, Oncohealth Institute, IIS-Fundación Jiménez Diaz, Autonomous University of Madrid, University Hospital "Fundación Jiménez Diaz", Avda. Reyes Católicos-2, 28040, Madrid, Spain
| | - Andrea Santos
- Translational Oncology Division, Oncohealth Institute, IIS-Fundación Jiménez Diaz, Autonomous University of Madrid, University Hospital "Fundación Jiménez Diaz", Avda. Reyes Católicos-2, 28040, Madrid, Spain
| | - Marta Sanz-Alvarez
- Pathology Department, Autonomous University of Madrid, University Hospital "Fundación Jiménez Diaz", 28040, Madrid, Spain
| | - Roberto Serna-Blasco
- Translational Oncology Division, Oncohealth Institute, IIS-Fundación Jiménez Diaz, Autonomous University of Madrid, University Hospital "Fundación Jiménez Diaz", Avda. Reyes Católicos-2, 28040, Madrid, Spain
| | - Melania Luque
- Pathology Department, Autonomous University of Madrid, University Hospital "Fundación Jiménez Diaz", 28040, Madrid, Spain
| | - Juan Madoz-Gúrpide
- Pathology Department, Autonomous University of Madrid, University Hospital "Fundación Jiménez Diaz", 28040, Madrid, Spain
| | - Federico Rojo
- Pathology Department, Autonomous University of Madrid, University Hospital "Fundación Jiménez Diaz", 28040, Madrid, Spain
| | - Jesús García-Foncillas
- Translational Oncology Division, Oncohealth Institute, IIS-Fundación Jiménez Diaz, Autonomous University of Madrid, University Hospital "Fundación Jiménez Diaz", Avda. Reyes Católicos-2, 28040, Madrid, Spain.
| |
Collapse
|
10
|
Gonzalez-Alonso P, Cristobal I, Zazo S, Martin-Aparicio E, Chamizo C, Madoz-Gurpide J, Rovira A, Eroles P, Lluch A, Albanell J, Rojo F. Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer Models. Curr Med Chem 2018; 25:1976-1998. [DOI: 10.2174/0929867323666161216144659] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2016] [Revised: 11/17/2016] [Accepted: 12/14/2016] [Indexed: 11/22/2022]
Abstract
Background:
Overexpression and amplification of the human epidermal growth
factor receptor 2 (HER2) occur in 20% of total breast carcinomas. HER2-overexpression is
implicated in disease initiation and progression and associated with poor prognosis. Trastuzumab,
a humanized monoclonal antibody, is the standard HER2-targeted therapy for early
and metastatic HER2-amplified breast cancer patients. Trastuzumab has significantly increased
clinical benefit in HER2+ metastatic and adjuvant settings; however, it is not effective
for many patients due to primary or acquired resistance to the drug. During the last decade,
many studies have revealed a number of novel molecular traits of HER2+ breast cancer, allowing
us to uncover the molecular mechanisms involved in trastuzumab resistance and develop
strategies to overcome resistance to therapy.
Objective:
In this review, we comprehensively addressed the current achievements in preclinical
studies; we discussed molecular mechanisms of acquired trastuzumab resistance in
HER2+ breast cancer models and potential therapeutic approaches based on the molecular
features for HER2+ breast cancer.
Conclusion:
Enhanced understanding of the molecular profiles in HER2+ breast cancer may
lead to the identification of novel biomarkers for the development of diagnostic approaches
and improvement of therapeutic targets for the prevention and treatment of trastuzumab resistant
HER2+ breast cancer.
Collapse
Affiliation(s)
- Paula Gonzalez-Alonso
- Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain
| | - Ion Cristobal
- Medical Oncology Department, Oncohealth Institute, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain
| | - Sandra Zazo
- Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain
| | - Ester Martin-Aparicio
- Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain
| | - Cristina Chamizo
- Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain
| | - Juan Madoz-Gurpide
- Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain
| | - Ana Rovira
- Cancer Research Program, Hospital del Mar Research Institute (IMIM), Medical Oncology Department, Hospital del Mar, E-08003 Barcelona, Spain
| | - Pilar Eroles
- Oncology and Hematology Department, Health Research Institute University Clinic Hospital of Valencia (INCLIVA), University of Valencia, E-46010 Valencia, Spain
| | - Ana Lluch
- Oncology and Hematology Department, Health Research Institute University Clinic Hospital of Valencia (INCLIVA), University of Valencia, E-46010 Valencia, Spain
| | - Joan Albanell
- Cancer Research Program, Hospital del Mar Research Institute (IMIM), Medical Oncology Department, Hospital del Mar, E-08003 Barcelona, Spain
| | - Federico Rojo
- Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundacion Jimenez Diaz, UAM (IIS-FJD, UAM), Avda. Reyes Catolicos, E-28040 Madrid, Spain
| |
Collapse
|
11
|
Manso R, Martínez-Magunacelaya N, Chamizo C, Rojo F, Piris MÁ, Rodriguez-Pinilla SM. Mutual regulation between BCL6 and a specific set of miRNAs controls TFH
phenotype in peripheral T-cell lymphoma. Br J Haematol 2017; 182:587-590. [DOI: 10.1111/bjh.14824] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Rebeca Manso
- Pathology Department; IIS-Fundación Jiménez Díaz; UAM; Madrid Spain
| | | | - Cristina Chamizo
- Pathology Department; IIS-Fundación Jiménez Díaz; UAM; Madrid Spain
| | - Federico Rojo
- Pathology Department; IIS-Fundación Jiménez Díaz; UAM; Madrid Spain
| | | | | |
Collapse
|
12
|
Zazo S, González-Alonso P, Martín-Aparicio E, Chamizo C, Cristóbal I, Arpí O, Rovira A, Albanell J, Eroles P, Lluch A, Madoz-Gúrpide J, Rojo F. Generation, characterization, and maintenance of trastuzumab-resistant HER2+ breast cancer cell lines. Am J Cancer Res 2016; 6:2661-2678. [PMID: 27904779 PMCID: PMC5126281] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2016] [Accepted: 09/19/2016] [Indexed: 06/06/2023] Open
Abstract
Trastuzumab became the therapy of choice for patients with HER2-positive breast cancer in 1998, and it has provided clinical benefit ever since. However, a significant percentage of patients show primary resistance to trastuzumab at diagnosis, and most patients with metastatic disease that initially respond to trastuzumab eventually progress (acquired resistance). Consequently, there is an urgent need to improve our knowledge of the mechanisms governing resistance, so that specific therapeutic strategies can be developed to provide improved efficacy. We generated new cell lines derived from BCCL through extended exposure to trastuzumab. Drug-conditioned populations were authenticated for their molecular profile and their resistance rate was determined. Heterogeneous HER2 amplification was observed across most of the BCCLs, ranging from cells without HER2 amplification to elevated HER2 gene copy numbers in others. Using a phospho-antibody array we analyzed the status of kinase receptors and effectors from different cellular pathways. This revealed that HER2, AKT, and S6RP presented high phosphorylation levels with specific variations between sensitive and resistant populations. In addition, differences in phosphorylation levels for several of those pathways targets were found between sensitive and resistant lines. Furthermore, a biochemical study characterized patterns of molecular alterations similar to those commonly described in breast cancer. Finally, a subcutaneous xenograft murine model confirmed the resistance to trastuzumab of the established cell line. We conclude that these resistant BCCLs can be a valuable tool to gain insight into the mechanisms of acquisition of trastuzumab resistance.
Collapse
Affiliation(s)
- Sandra Zazo
- Department of Pathology, IIS-Fundación Jiménez Díaz, UAME-28040 Madrid, Spain
| | | | | | - Cristina Chamizo
- Department of Pathology, IIS-Fundación Jiménez Díaz, UAME-28040 Madrid, Spain
| | - Ion Cristóbal
- Translational Oncology Division, Onco Health Institute, Health Research Institute FJD-UAM, University Hospital Fundación Jiménez DíazMadrid, Spain
| | - Oriol Arpí
- Department of Medical Oncology, Hospital del MarBarcelona, Spain
| | - Ana Rovira
- Department of Medical Oncology, Hospital del MarBarcelona, Spain
| | - Joan Albanell
- Department of Medical Oncology, Hospital del MarBarcelona, Spain
| | - Pilar Eroles
- Institute of Health Research INCLIVAValencia, Spain
| | - Ana Lluch
- Institute of Health Research INCLIVAValencia, Spain
| | - Juan Madoz-Gúrpide
- Department of Pathology, IIS-Fundación Jiménez Díaz, UAME-28040 Madrid, Spain
| | - Federico Rojo
- Department of Pathology, IIS-Fundación Jiménez Díaz, UAME-28040 Madrid, Spain
| |
Collapse
|
13
|
Rincón R, Zazo S, Chamizo C, Manso R, González-Alonso P, Martín-Aparicio E, Cristóbal I, Cañadas C, Perona R, Lluch A, Eroles P, García-Foncillas J, Albanell J, Rovira A, Madoz-Gúrpide J, Rojo F. c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer. Mol Cancer Ther 2016; 15:2780-2790. [PMID: 27599524 DOI: 10.1158/1535-7163.mct-15-0920] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2015] [Accepted: 08/07/2016] [Indexed: 11/16/2022]
Abstract
MAPK phosphatase-1 (MKP-1) is overexpressed during malignant transformation of the breast in many patients, and it is usually associated with chemoresistance through interference with JNK-driven apoptotic pathways. Although the molecular settings of the mechanism have been documented, details about the contribution of MKP-1 to the failure of chemotherapeutic interventions are unclear. Transient overexpression of MKP-1 and treatment with JNK-modulating agents in breast carcinoma cells confirmed the mediation of MKP-1 in the resistance to taxanes and anthracyclines in breast cancer, through the inactivation of JNK1/2. We next assessed MKP-1 expression and JNK1/2 phosphorylation status in a large cohort of samples from 350 early breast cancer patients treated with adjuvant anthracycline-based chemotherapy. We detected that MKP-1 overexpression is a recurrent event predominantly linked to dephosphorylation of JNK1/2 with an adverse impact on relapse of the tumor and overall and disease-free survival. Moreover, MKP-1 and p-JNK1/2 determinations in 64 locally advanced breast cancer patients treated with neoadjuvant taxane-based chemotherapy showed an inverse correlation between MKP-1 overexpression (together with JNK1/2 inhibition) and the pathologic response of the tumors. Our results emphasize the importance of MKP-1 as a potential predictive biomarker for a subset of breast cancer patients with worse outcome and less susceptibility to treatment. Mol Cancer Ther; 15(11); 2780-90. ©2016 AACR.
Collapse
Affiliation(s)
- Raúl Rincón
- Pathology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | - Sandra Zazo
- Pathology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | - Cristina Chamizo
- Pathology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | - Rebeca Manso
- Pathology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | | | | | - Ion Cristóbal
- Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital Fundación Jiménez Díaz, Madrid, Spain
| | - Carmen Cañadas
- Pathology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain
| | - Rosario Perona
- "Alberto Sols" Biomedical Research Institute CSIC-UAM, Madrid, Spain
| | - Ana Lluch
- Institute of Health Research INCLIVA, Valencia, Spain
| | - Pilar Eroles
- Institute of Health Research INCLIVA, Valencia, Spain
| | - Jesús García-Foncillas
- Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital Fundación Jiménez Díaz, Madrid, Spain
| | - Joan Albanell
- Medical Oncology Department, Hospital del Mar, Barcelona, Spain
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain
- Universitat Pompeu Fabra, Barcelona, Spain
| | - Ana Rovira
- Medical Oncology Department, Hospital del Mar, Barcelona, Spain
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain
| | | | - Federico Rojo
- Pathology Department, IIS-Fundación Jiménez Díaz, UAM, Madrid, Spain.
| |
Collapse
|
14
|
Chamizo C, Zazo S, Dómine M, Cristóbal I, García-Foncillas J, Rojo F, Madoz-Gúrpide J. Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer. BMC Pulm Med 2015; 15:132. [PMID: 26502926 PMCID: PMC4623912 DOI: 10.1186/s12890-015-0132-x] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2015] [Accepted: 10/19/2015] [Indexed: 11/10/2022] Open
Abstract
Background Although it has been suggested that a high level of thymidylate synthase (TYMS) gene expression in malignant tumors is related to reduced sensitivity to the antifolate drug pemetrexed, no direct evidence for such an association has been demonstrated in routine clinical samples from patients treated with the drug. The purpose of this study was to quantitatively assess the impact of TYMS gene expression in tumor cells as a predictor of the efficacy of pemetrexed therapy in patients with advanced non-small cell lung cancer (NSCLC) treated at our institution. Methods Sixty-two NSCLC patients were included in this study: 16 patients received platins-pemetrexed as first-line NSCLC, and 46 pemetrexed in monotherapy as second- or subsequent-line treatment. Total mRNA was isolated and the expression of TYMS was analyzed by RT-qPCR. TYMS levels were calibrated against expression in normal lung tissue. Results TYMS overexpression was detected in 61 % of patients and low expression in 39 %. The response rate for patients with low TYMS expression was 0.29 compared with 0.03 in patients with overexpression (P = 0.025). A significant benefit was observed in patients with low expression both in time to progression (average TTP = 56 vs. 23 months, P = 0.001) and in overall survival (average OS = 60 vs. 25 months, P = 0.002). Conclusions TYMS overexpression in tumor cells correlated with a reduced response to pemetrexed-containing chemotherapy and might be used as a predictive biomarker in advanced NSCLC patients.
Collapse
Affiliation(s)
- Cristina Chamizo
- Cancer Biomarkers Research Group, Fundacion Jimenez Diaz University Hospital Health Research Institute, UAM, Madrid, Spain.
| | - Sandra Zazo
- Cancer Biomarkers Research Group, Fundacion Jimenez Diaz University Hospital Health Research Institute, UAM, Madrid, Spain.
| | - Manuel Dómine
- Translational Oncology Division, Oncohealth Institute, Fundacion Jimenez Diaz University Hospital, Madrid, Spain.
| | - Ion Cristóbal
- Translational Oncology Division, Oncohealth Institute, Fundacion Jimenez Diaz University Hospital, Madrid, Spain.
| | - Jesús García-Foncillas
- Translational Oncology Division, Oncohealth Institute, Fundacion Jimenez Diaz University Hospital, Madrid, Spain.
| | - Federico Rojo
- Cancer Biomarkers Research Group, Fundacion Jimenez Diaz University Hospital Health Research Institute, UAM, Madrid, Spain.
| | - Juan Madoz-Gúrpide
- Cancer Biomarkers Research Group, Fundacion Jimenez Diaz University Hospital Health Research Institute, UAM, Madrid, Spain.
| |
Collapse
|
15
|
Madoz-Gúrpide J, Zazo S, Chamizo C, Casado V, Caramés C, Gavín E, Cristóbal I, García-Foncillas J, Rojo F. Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer. J Transl Med 2015; 13:282. [PMID: 26319934 PMCID: PMC4552997 DOI: 10.1186/s12967-015-0633-7] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2015] [Accepted: 08/10/2015] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Activation of the MET oncogene promotes tumor growth, invasion and metastasis in several tumor types. Additionally, MET is activated as a compensatory pathway in the presence of EGFR blockade, thus resulting in a mechanism of resistance to EGFR inhibitors. METHODS We have investigated the impact of HGF and MET expression, MET activation (phosphorylation), MET gene status, and MET-activating mutations on cetuximab sensitivity in recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) patients. RESULTS A single-institution retrospective analysis was performed in 57 patients. MET overexpression was detected in 58% patients, MET amplification in 39% and MET activation (p-MET) in 30%. Amplification was associated with MET overexpression. Log-rank testing showed significantly worse outcomes in recurrent/metastatic, MET overexpressing patients for progression-free survival and overall survival. Activation of MET was correlated with worse PFS and OS. In multivariate logistic regression analysis, p-MET was an independent prognostic factor for PFS. HGF overexpression was observed in 58% patients and was associated with MET phosphorylation, suggesting a paracrine activation of the receptor. CONCLUSIONS HGF/MET pathway activation correlated with worse outcome in recurrent/metastatic HNSCC patients. When treated with a cetuximab-based regimen, these patients correlated with worse outcome. This supports a dual blocking strategy of HGF/MET and EGFR pathways for the treatment of patients with recurrent/metastatic HNSCC.
Collapse
Affiliation(s)
- Juan Madoz-Gúrpide
- Molecular Pathology Laboratory, IIS-Fundacion Jimenez Diaz, UAM, Avda. Reyes Catolicos 2, 28040, Madrid, Spain.
| | - Sandra Zazo
- Molecular Pathology Laboratory, IIS-Fundacion Jimenez Diaz, UAM, Avda. Reyes Catolicos 2, 28040, Madrid, Spain.
| | - Cristina Chamizo
- Molecular Pathology Laboratory, IIS-Fundacion Jimenez Diaz, UAM, Avda. Reyes Catolicos 2, 28040, Madrid, Spain.
| | | | | | - Eduardo Gavín
- Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, Avda. Reyes Catolicos 2, 28040, Madrid, Spain.
| | - Ion Cristóbal
- Translational Oncology Department, IIS-Fundacion Jimenez Diaz, UAM, Madrid, Spain.
| | | | - Federico Rojo
- Molecular Pathology Laboratory, IIS-Fundacion Jimenez Diaz, UAM, Avda. Reyes Catolicos 2, 28040, Madrid, Spain. .,Pathology Department, IIS-Fundacion Jimenez Diaz, UAM, Avda. Reyes Catolicos 2, 28040, Madrid, Spain.
| |
Collapse
|
16
|
González-Alonso P, Chamizo C, Moreno V, Madoz-Gúrpide J, Carvajal N, Daoud L, Zazo S, Martín-Aparicio E, Cristóbal I, Rincón R, García-Foncillas J, Rojo F. Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma. Int J Mol Sci 2015; 16:19447-57. [PMID: 26287187 PMCID: PMC4581306 DOI: 10.3390/ijms160819447] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2015] [Revised: 08/05/2015] [Accepted: 08/10/2015] [Indexed: 02/03/2023] Open
Abstract
Mutations in Human Epidermal Growth Factor Receptors (HER) are associated with poor prognosis of several types of solid tumors. Although HER-mutation detection methods are currently available, such as Next-Generation Sequencing (NGS), alternative pyrosequencing allow the rapid characterization of specific mutations. We developed specific PCR-based pyrosequencing assays for identification of most prevalent HER2 and HER3 mutations, including S310F/Y, R678Q, L755M/P/S/W, V777A/L/M, 774-776 insertion, and V842I mutations in HER2, as well as M91I, V104M/L, D297N/V/Y, and E332E/K mutations in HER3. We tested 85 Formalin Fixed and Paraffin Embbeded (FFPE) samples and we detected three HER2-V842I mutations in colorectal carcinoma (CRC), ovarian carcinoma, and pancreatic carcinoma patients, respectively, and a HER2-L755M mutation in a CRC specimen. We also determined the presence of a HER3-E332K mutation in an urothelial carcinoma sample, and two HER3-D297Y mutations, in both gastric adenocarcinoma and CRC specimens. The D297Y mutation was previously detected in breast and gastric tumors, but not in CRC. Moreover, we found a not-previously-described HER3-E332E synonymous mutation in a retroperitoneal leiomyosarcoma patient. The pyrosequencing assays presented here allow the detection and characterization of specific HER2 and HER3 mutations. These pyrosequencing assays might be implemented in routine diagnosis for molecular characterization of HER2/HER3 receptors as an alternative to complex NGS approaches.
Collapse
Affiliation(s)
- Paula González-Alonso
- Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Avda. Reyes Católicos.
| | - Cristina Chamizo
- Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Avda. Reyes Católicos.
| | | | - Juan Madoz-Gúrpide
- Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Avda. Reyes Católicos.
| | - Nerea Carvajal
- Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Avda. Reyes Católicos.
| | - Lina Daoud
- Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Avda. Reyes Católicos.
| | - Sandra Zazo
- Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Avda. Reyes Católicos.
| | - Ester Martín-Aparicio
- Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Avda. Reyes Católicos.
| | | | - Raúl Rincón
- Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Avda. Reyes Católicos.
| | | | - Federico Rojo
- Group of Cancer Biomarkers, Pathology Department, Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Avda. Reyes Católicos.
| |
Collapse
|
17
|
García-Parra J, Dalmases A, Morancho B, Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, Eroles P, Servitja S, Tusquets I, Yelamos J, Lluch A, Arribas J, Rojo F, Rovira A, Albanell J. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer. Eur J Cancer 2014; 50:2725-34. [PMID: 25128455 DOI: 10.1016/j.ejca.2014.07.004] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2013] [Revised: 06/12/2014] [Accepted: 07/07/2014] [Indexed: 11/30/2022]
Abstract
AIM Poly (ADP-ribose) polymerase (PARP) inhibitors have shown promising results in Breast Cancer (BRCA) deficient breast cancer, but not in molecularly unselected patient populations. Two lines of research in this field are needed: the identification of novel subsets of patients that could potentially benefit from PARP inhibitors and the discovery of suitable targeted therapies for combination strategies. METHODS We tested PARP inhibition, alone or combined with the anti-HER2 antibody trastuzumab on HER2+ breast cancer. We used two PARP inhibitors in clinical development, olaparib and rucaparib, as well as genetic downmodulation of PARP-1 for in vitro studies. DNA damage was studied by the formation of γH2AX foci and comet assay. Finally, the in vivo anti-tumour effect of olaparib and trastuzumab was examined in nude mice subcutaneously implanted with BT474 cells. RESULTS In a panel of four HER2 overexpressing breast cancer cell lines, both olaparib and rucaparib significantly decreased cell growth and enhanced anti-tumour effects of trastuzumab. Cells exposed to olaparib and trastuzumab had greater DNA damage than cells exposed to each agent alone. Mechanistic exploratory assays showed that trastuzumab downmodulated the homologous recombination protein proliferating cell nuclear antigen (PCNA). Combination treatment in the BT474 xenograft model resulted in enhanced growth inhibition, reduced tumour cell proliferation, and increased DNA damage and apoptosis. CONCLUSION Taken together, our results show that PARP inhibition has antitumour effects and increases trastuzumab activity in HER2 overexpressing breast cancer. These findings make this novel combination a promising strategy for clinical development.
Collapse
Affiliation(s)
- Jetzabel García-Parra
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | - Alba Dalmases
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | - Beatriz Morancho
- Preclinical Research Program, Valld'Hebron Institute of Oncology (VHIO), Barcelona, Spain
| | - Oriol Arpí
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | - Silvia Menendez
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | - MohammadA Sabbaghi
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | - Sandra Zazo
- Pathology Department, IIS-Fundación Jiménez Díaz, Madrid, Spain
| | | | - Juan Madoz
- Pathology Department, IIS-Fundación Jiménez Díaz, Madrid, Spain
| | - Pilar Eroles
- Institute of Health Research INCLIVA, Valencia, Spain
| | - Sonia Servitja
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | - Ignasi Tusquets
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Medical Oncology Department, Hospital del Mar, Barcelona, Spain; Autonomous University of Barcelona, Spain
| | - Jose Yelamos
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Immunology Department, Hospital del Mar, Barcelona, Spain
| | - Ana Lluch
- Oncology and Hematology Department, Hospital Clinico Universitario, Valencia, Spain; Valencia Central University, Spain
| | - Joaquin Arribas
- Preclinical Research Program, Valld'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Department of Biochemistry and Molecular Biology, Universitat Autonoma de Barcelona, Bellaterra, Spain; Institució Catalana de Recerca I Estudis Avançats (ICREA), Barcelona, Spain
| | - Federico Rojo
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Pathology Department, IIS-Fundación Jiménez Díaz, Madrid, Spain; Pathology Department, Hospital del Mar, Barcelona, Spain
| | - Ana Rovira
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | - Joan Albanell
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Medical Oncology Department, Hospital del Mar, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain.
| |
Collapse
|
18
|
Tusquets I, Garcia-Parra J, Dalmases A, Morancho B, Arpi O, Menendez S, Sabbaghi MA, Zazo S, Chamizo C, Madoz J, Eroles P, Servitja S, Yelamos J, Lluch A, Arribas J, Rojo F, Rovira A, Albanell J. Preclinical in vitro and in vivo evaluation of antitumor activity of poly (ADP-ribose) polymerase inhibition and trastuzumab combined therapy in HER2-overexpressing breast cancer. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | - Jetzabel Garcia-Parra
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | - Alba Dalmases
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | - Beatriz Morancho
- Preclinical Research Program, Valld’Hebron Institute of Oncology, Barcelona, Spain
| | - Oriol Arpi
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | - Silvia Menendez
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | - Mohammad Ali Sabbaghi
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Medical Oncology Department, Hospital del Mar, Barcelona, Spain
| | - Sandra Zazo
- Translational Oncology Division. Hospital Universitario Fundacion Jimenez Díaz, Madrid, Spain
| | - Cristina Chamizo
- Pathology Department, IIS-Fundación Jiménez Díaz, Madrid, Spain;, Madrid, Spain
| | - Juan Madoz
- Translational Oncology Division. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Pilar Eroles
- Institute of Health Research (INCLIVA), Valencia, Spain
| | - Sonia Servitja
- Medical Oncology Department. Hospital del Mar, Barcelona, Spain
| | - Jose Yelamos
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain; Immunology Department, Hospital del Mar, Barcelona, Spain
| | - Ana Lluch
- Hospital Clinico Universitario de Valencia, Valencia, Spain
| | - JoaquÃÂn Arribas
- Preclinical Research Program, Valld’Hebron Institute of Oncology; Department of Biochemistry and Molecular Biology, Universitat Autonoma de Barcelona, Bellaterra, Spain; Institució Catalana deRecerca I Estudis Avançats (ICREA), Barcelona, Spain;, Barcelona, Spain
| | - Federico Rojo
- Pathology Department, IMIM-Hospital del Mar, Barcelona, Spain
| | | | | |
Collapse
|
19
|
del Puerto-Nevado L, Rojo F, Zazo S, Caramés C, Rubio G, Vega R, Chamizo C, Casado V, Martínez-Useros J, Rincón R, Rodríguez-Remírez M, Borrero-Palacios A, Cristóbal I, Madoz-Gúrpide J, Aguilera O, García-Foncillas J. Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy. Br J Cancer 2014; 110:2700-7. [PMID: 24786599 PMCID: PMC4037833 DOI: 10.1038/bjc.2014.225] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Revised: 02/27/2014] [Accepted: 04/04/2014] [Indexed: 01/15/2023] Open
Abstract
Background: Sunitinib represents a widely used therapy for metastatic renal cell carcinoma patients. Even so, there is a group of patients who show toxicity without clinical benefit. In this work, we have analysed pivotal molecular targets involved in angiogenesis (vascular endothelial growth factor (VEGF)-A, VEGF receptor 2 (KDR), phosphorylated (p)KDR and microvascular density (MVD)) to test their potential value as predictive biomarkers of clinical benefit in sunitinib-treated renal cell carcinoma patients. Methods: Vascular endothelial growth factor-A, KDR and pKDR-Y1775 expression as well as CD31, for MVD visualisation, were determined by immunohistochemistry in 48 renal cell carcinoma patients, including 23 metastatic cases treated with sunitinib. Threshold was defined for each biomarker, and univariate and multivariate analyses for progression-free survival (PFS) and overall survival (OS) were carried out. Results: The HistoScore mean value obtained for VEGF-A was 121.6 (range, 10–300); for KDR 258.5 (range, 150–300); for pKDR-Y1775 10.8 (range, 0–65) and the mean value of CD31-positive structures for MVD visualisation was 49 (range, 10–126). Statistical differences for PFS (P=0.01) and OS (P=0.007) were observed for pKDR-Y1775 in sunitinib-treated patients. Importantly, pKDR-Y1775 expression remained significant after multivariate Cox analysis for PFS (P=0.01; HR: 5.35, 95% CI, 1.49–19.13) and for OS (P=0.02; HR: 5.13, 95% CI, 1.25–21.05). Conclusions: Our results suggest that the expression of phosphorylated (i.e., activated) KDR in tumour stroma might be used as predictive biomarker for the clinical outcome in renal cell carcinoma first-line sunitinib-treated patients.
Collapse
Affiliation(s)
- L del Puerto-Nevado
- Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundación Jiménez Díaz', Avenida Reyes Católicos, 2, 28040 Madrid, Spain
| | - F Rojo
- Department of Pathology, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundación Jiménez Díaz', Avenida Reyes Católicos, 2, 28040 Madrid, Spain
| | - S Zazo
- Department of Pathology, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundación Jiménez Díaz', Avenida Reyes Católicos, 2, 28040 Madrid, Spain
| | - C Caramés
- Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundación Jiménez Díaz', Avenida Reyes Católicos, 2, 28040 Madrid, Spain
| | - G Rubio
- Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundación Jiménez Díaz', Avenida Reyes Católicos, 2, 28040 Madrid, Spain
| | - R Vega
- Department of Pathology, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundación Jiménez Díaz', Avenida Reyes Católicos, 2, 28040 Madrid, Spain
| | - C Chamizo
- Department of Pathology, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundación Jiménez Díaz', Avenida Reyes Católicos, 2, 28040 Madrid, Spain
| | - V Casado
- Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundación Jiménez Díaz', Avenida Reyes Católicos, 2, 28040 Madrid, Spain
| | - J Martínez-Useros
- Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundación Jiménez Díaz', Avenida Reyes Católicos, 2, 28040 Madrid, Spain
| | - R Rincón
- Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundación Jiménez Díaz', Avenida Reyes Católicos, 2, 28040 Madrid, Spain
| | - M Rodríguez-Remírez
- Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundación Jiménez Díaz', Avenida Reyes Católicos, 2, 28040 Madrid, Spain
| | - A Borrero-Palacios
- Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundación Jiménez Díaz', Avenida Reyes Católicos, 2, 28040 Madrid, Spain
| | - I Cristóbal
- Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundación Jiménez Díaz', Avenida Reyes Católicos, 2, 28040 Madrid, Spain
| | - J Madoz-Gúrpide
- Department of Pathology, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundación Jiménez Díaz', Avenida Reyes Católicos, 2, 28040 Madrid, Spain
| | - O Aguilera
- Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundación Jiménez Díaz', Avenida Reyes Católicos, 2, 28040 Madrid, Spain
| | - J García-Foncillas
- Translational Oncology Division, Oncohealth Institute, Health Research Institute FJD-UAM, University Hospital 'Fundación Jiménez Díaz', Avenida Reyes Católicos, 2, 28040 Madrid, Spain
| |
Collapse
|
20
|
Rojo F, Domingo L, Sala M, Zazo S, Chamizo C, Menendez S, Arpi O, Corominas JM, Bragado R, Servitja S, Tusquets I, Nonell L, Macià F, Martínez J, Rovira A, Albanell J, Castells X. Gene expression profiling in true interval breast cancer reveals overactivation of the mTOR signaling pathway. Cancer Epidemiol Biomarkers Prev 2013; 23:288-99. [PMID: 24347552 DOI: 10.1158/1055-9965.epi-13-0761] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND The development and progression of true interval breast cancers (tumors that truly appear after a negative screening mammogram) is known to be different from screen-detected cancers. However, the worse clinical behavior of true interval cancers is not fully understood from a biologic basis. We described the differential patterns of gene expression through microarray analysis in true interval and screen-detected cancers. METHODS An unsupervised exploratory gene expression profile analysis was performed on 10 samples (true interval cancers = 5; screen-detected cancers = 5) using Affymetrix Human Gene 1.0ST arrays and interpreted by Ingenuity Pathway Analysis. Differential expression of selected genes was confirmed in a validation series of 91 tumors (n = 12; n = 79) by immunohistochemistry and in 24 tumors (n = 8; n = 16) by reverse transcription quantitative PCR (RT-qPCR), in true interval and screen-detected cancers, respectively. RESULTS Exploratory gene expression analysis identified 1,060 differentially expressed genes (unadjusted P < 0.05) between study groups. On the basis of biologic implications, four genes were further validated: ceruloplasmin (CP) and ribosomal protein S6 kinase, 70 kDa, polypeptide 2 (RPS6KB2), both upregulated in true interval cancers; and phosphatase and tensin homolog (PTEN) and transforming growth factor beta receptor III (TGFBR3), downregulated in true interval cancers. Their differential expression was confirmed by RT-qPCR and immunohistochemistry, consistent with mTOR pathway overexpression in true interval cancers. CONCLUSIONS True interval and screen-detected cancers show differential expression profile both at gene and protein levels. The mTOR signaling is significantly upregulated in true interval cancers, suggesting this pathway may mediate their aggressiveness. IMPACT Linking epidemiologic factors and mTOR activation may be the basis for future personalized screening strategies in women at risk of true interval cancers.
Collapse
Affiliation(s)
- Federico Rojo
- Authors' Affiliations: Departments of Pathology and Immunology, IIS-Fundación Jiménez Díaz, Madrid; Cancer Research Program; Microarray Core Facility (SAM), IMIM (Hospital del Mar Medical Research Institute); Department of Epidemiology and Evaluation, Hospital del Mar; Research Network on Health Services in Chronic Diseases (REDISSEC); Departments of Pathology, Medical Oncology, and Radiology Department, Hospital del Mar; and Universitat Pompeu Fabra, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Garcia-Foncillas J, Domine M, Rojo F, Hernandez T, Zazo S, Serrano G, Chamizo C, Carames C, Carvajal N, Moreno I, Perez-Gonzalez N, Leon A, Auz CL, Martin-Valades JI, Madoz J, Lobo F. VEGF-A 165 family of isoforms as predictive biomarkers in patients with nonsquamous non-small cell lung cancer (NSCLC) treated with bevacizumab. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.e19109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19109 Background: Bevacizumab is a recombinant monoclonal humanized antibody to vascular endothelial growth factor (VEGF) that improves Time to Progression (TTP) in patients with advanced non-squamous NSCLC in combination with a doublet of platins, but currently no proven predictive markers exist. The VEGF-A 165 splice variant has been described as the most abundant and active isoform in cancer. Exon 8 splice modifications of VEGF 165 generates the VEGF-A 165a family of isoforms, which has a pro-angiogenic effect, and VEGF-A 165b family, with an anti-angiogenic activity. This study is aimed to explore the role of VEGF165a and VEGF165b expression in tumors as predictive biomarkers of efficacy in patients with NSCLC treated with platins plus bevacizumab. Methods: 22 patients were included (20 adenocarcinomas and 2 large cell carcinomas): 5 received carboplatin-taxol-bevacizumab, 14 carboplatin-taxotere-bevacizumab and 3 cisplatin-gemcitabine-bevacizumab. Total RNA was isolated by RNeasy FFPE procedure. VEGF165a and VEGF165b expression was analyzed by RT-qPCR using appropriate specific primers and probes. Individual VEGF165a and VEGF165b family of isoforms expression was calibrated to normal tissue and the ratio between both isoforms was calculated. Results: VEGF165a overexpression was detected in 14 (63.6%) cases and VEGF165b overexpression in 15 (68.2%). Individual overexpression for each family of isoforms was not predictive of benefit to bevacizumab therapy (p=0.933 and 0.166). However, the ratio between VEGF165a and VEGF165b was associated with TTP, correlating a predominant expression of pro-angiogenic VEGF165a with a significant benefit compared with cases with predominant VEGF165b expression (median TTP, 15 vs. 8 months respectively, p=0.005). The expression of both isoforms did not impact on OS (p=0.477). Conclusions: The overexpression of VEGF165a and low expression of VEGF165b family of isoforms correlated with benefit to anti-angiogenic therapy in NSCLC patients, supporting a potential use as predictive biomarkers for bevacizumab treatment in stage IV non-squamous NSCLC.
Collapse
Affiliation(s)
- Jesus Garcia-Foncillas
- Oncology Department and Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Manuel Domine
- Oncology Department and Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Federico Rojo
- Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Tatiana Hernandez
- Oncology Department and Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Sandra Zazo
- Translational Oncology Division. Hospital Universitario Fundacion Jimenez Díaz, Madrid, Spain
| | - Gloria Serrano
- Oncology Department and Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Cristina Chamizo
- Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Cristina Carames
- Oncology Department and Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Nerea Carvajal
- Translational Oncology Division. Hospital Universitario. Fundacion Jimenez Diaz, Madrid, Spain
| | - Irene Moreno
- Oncology Department and Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Nuria Perez-Gonzalez
- Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Ana Leon
- Oncology Department. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Carmen Laura Auz
- Translational Oncology Division Fundacion Jimenez Diaz, Madrid, Spain
| | | | - Juan Madoz
- Translational Oncology Division. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Francisco Lobo
- Oncology Department. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| |
Collapse
|
22
|
Domine M, Rojo F, Hernandez T, Zazo S, Serrano G, Chamizo C, Carames C, Madoz J, Moreno I, Perez-Gonzalez N, Ortega C, Carvajal N, Lobo F, Auz CL, Casado V, Rubio G, Oruezabal M, Lendinez A, Leon A, Garcia-Foncillas J. KRAS and EGFR status as predictive markers of response and time to progression in EGFR wild-type stage IV non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine-kinase inhibitors. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.e19000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e19000 Background: KRAS mutations on codons 12, 13 and 61 result in the constitutive activation of protein, which may render tumor cells independent of epidermal growth factor receptor (EGFR) signalling and thereby resistant to tyrosine-kinase inhibitor (TKI) therapy in NSCLC patients. This study was aimed to evaluate the associations of KRAS and EGFR copy number alteration and mutations with response and time to progression (TTP) in EGFR TKI-treated patients. Methods: 84 samples from NSCLS patients treated with erlotinib or gefitinib were analyzed for KRAS and EGFR mutation status by cobas KRAS and EGFR Mutation Tests (Roche). EGFR copy number was determined by fluorescent in situ hybridization (FISH, Abbott Molecular) and amplification was defined with three or more gene copies in tumor. Results: KRAS mutation was detected in 15 (17.8%) cases, EGFR mutation in 27 (32.1%) and EGFR amplification in 8 (9.5%). Significant differences were detected in response rates for wild-type (0.2) and mutant KRAS (0.0) (p=0.023), for wild-type (0.12) and mutant EGFR (0.39) (p=0.007), and for non-amplified (0.18) and EGFR-amplified (0.71) patients (p=0.005). Additionally, significant benefit from TKI therapy was observed for KRAS wild-type compared with KRAS-mutated patients (median TTP 7 vs. 3 months, p=0.001), for EGFR-mutated compared with wild-type patients (14 vs. 4 months, p=0.004) and for EGFR-amplification in contrast to non-amplified cases (11 vs. 5 months, p=0.001). KRAS and EGFR mutations or EGFR amplification did not correlated with overall survival (18 vs. 19 months, p=0.406; 16 vs. 21 p=0.094; 25 vs. 17 months, p=0.103, respectively). Combined analysis of favourable status of three biomarkers strongly predicted benefit to TKI therapy (median TTP 15 vs. 3 months, p<0.001). Conclusions: Combined analysis ofKRAS mutation, EGFR mutation and EGFR amplification in EGFR TKI-treated NSCLC might provide superior predictive information than single biomarker study in these patients.
Collapse
Affiliation(s)
- Manuel Domine
- Oncology Department and Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Federico Rojo
- Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Tatiana Hernandez
- Oncology Department and Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Sandra Zazo
- Translational Oncology Division. Hospital Universitario Fundacion Jimenez Díaz, Madrid, Spain
| | - Gloria Serrano
- Oncology Department and Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Cristina Chamizo
- Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Cristina Carames
- Oncology Department and Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Juan Madoz
- Translational Oncology Division. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Irene Moreno
- Oncology Department and Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Nuria Perez-Gonzalez
- Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Carolina Ortega
- Oncology Department. Hospital Universitario Infanta Elena, Valdemoro, Madrid, Spain
| | - Nerea Carvajal
- Translational Oncology Division. Hospital Universitario. Fundacion Jimenez Diaz, Madrid, Spain
| | - Francisco Lobo
- Oncology Department. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Carmen Laura Auz
- Translational Oncology Division Fundacion Jimenez Diaz, Madrid, Spain
| | - Victoria Casado
- Oncology Department. Hospital Universitario. Fundacion Jimenez Diaz, Madrid, Spain
| | - Gustavo Rubio
- Oncology Department. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Mauro Oruezabal
- Department of Oncology. Hospital Universitario Rey Juan Carlos, Mostoles, Madrid, Spain
| | - Alberto Lendinez
- Oncology Department. Hospital Universitario Infanta Elena, Madrid, Spain
| | - Ana Leon
- Oncology Department. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Jesus Garcia-Foncillas
- Oncology Department and Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| |
Collapse
|
23
|
Rojo F, Domine M, Zazo S, Chamizo C, Serrano G, Carames C, Perez-Gonzalez N, Hernandez T, Auz CL, Carvajal N, Moreno I, Martin-Valades JI, Izarzugaza Y, Lendinez A, Martinez-Ammoros B, Arranz JL, Madoz J, Leon A, Lobo F, Garcia-Foncillas J. Thymidylate synthase expression as predictive biomarker of pemetrexed sensitivity in advanced cancer patients. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.11089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
11089 Background: Although a high level of thymidylate synthase (TS) expression in malignant tumours has been suggested to be related to a reduced sensitivity to the antifolate drug pemetrexed, no direct evidence for such an association has been demonstrated in routine clinical samples from patients treated with this drug. The purpose of this study was to evaluate the impact of quantitative TS expression in tumor cells as predictor of the efficacy in patients with advanced non-small cell lung cancer, small cell lung cancer (SCLC) and mesothelioma treated with pemetrexed in our institution. Methods: 54 patients were included in this study: 40 stage IV NSCLC (26 adenocarcinomas, 11 large cell, and 3 squamous cell carcinoma), 3 SCLC and 11 mesothelioma. 21 patients received platins-pemetrexed as first line NSCLC, 20 pemetrexed in monotherapy as second and further lines and 3 carboplatin-pemetrexed fo extensive disease SCLC. Total RNA was isolated by RNeasy FFPE procedure (Qiagen). The expression of TS was analyzed by RT-qPCR using appropriate mRNA specific primers and probes in LightCycler 480II platform at 45 cycles. TS levels was calibrated to expression in normal tissue. Results: From 54 cases, TS expression data were available in 32 cases, detecting overexpression in 23 (71.8%) and low expression in 9 (28.2%) patients. The response rate for patients with low TS expression was 0.63 compared with 0.15 in patients with overexpression (p=0.015). A significant benefit in time to progression was observed in patients with low expression (median TTP 12 vs. 2 months respectively, p= 0.002), whereas did not impact on overall survival (median OS 20 vs. 19 months respectively, p= 0.595). Conclusions: TS overexpression in tumor cells correlated with a reduced response to pemetrexed-containing chemotherapy and might be used as a predictive biomarker in advanced lung and mesothelioma cancer patients.
Collapse
Affiliation(s)
- Federico Rojo
- Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | | | - Sandra Zazo
- Translational Oncology Division. Hospital Universitario Fundacion Jimenez Díaz, Madrid, Spain
| | - Cristina Chamizo
- Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Gloria Serrano
- Oncology Department and Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Cristina Carames
- Oncology Department and Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Nuria Perez-Gonzalez
- Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Tatiana Hernandez
- Oncology Department and Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Carmen Laura Auz
- Translational Oncology Division Fundacion Jimenez Diaz, Madrid, Spain
| | - Nerea Carvajal
- Translational Oncology Division. Hospital Universitario. Fundacion Jimenez Diaz, Madrid, Spain
| | - Irene Moreno
- Oncology Department and Translational Oncology Division. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | | | - Yann Izarzugaza
- Oncology Department, Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
| | - Alberto Lendinez
- Oncology Department. Hospital Universitario Infanta Elena, Madrid, Spain
| | | | - Juan Luis Arranz
- Oncology Department. Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
| | - Juan Madoz
- Translational Oncology Division. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - Ana Leon
- Oncology Department. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Francisco Lobo
- Oncology Department. Hospital Universitario Fundacion Jimenez Diaz, Madrid, Spain
| | - Jesus Garcia-Foncillas
- Oncology Department, Hospital Universitario Fundación Jiménez Díaz, Universidad Autónoma de Madrid, Madrid, Spain
| |
Collapse
|
24
|
Rojo F, García-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, Eroles P, Chamizo C, Servitja S, Ramírez-Merino N, Lobo F, Bellosillo B, Corominas JM, Yelamos J, Serrano S, Lluch A, Rovira A, Albanell J. Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol 2012; 23:1156-1164. [PMID: 21908496 DOI: 10.1093/annonc/mdr361] [Citation(s) in RCA: 123] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/06/2023] Open
Abstract
BACKGROUND Poly(ADP-ribose)polymerase-1 (PARP-1) is a highly promising novel target in breast cancer. However, the expression of PARP-1 protein in breast cancer and its associations with outcome are yet poorly characterized. PATIENTS AND METHODS Quantitative expression of PARP-1 protein was assayed by a specific immunohistochemical signal intensity scanning assay in a range of normal to malignant breast lesions, including a series of patients (N = 330) with operable breast cancer to correlate with clinicopathological factors and long-term outcome. RESULTS PARP-1 was overexpressed in about a third of ductal carcinoma in situ and infiltrating breast carcinomas. PARP-1 protein overexpression was associated to higher tumor grade (P = 0.01), estrogen-negative tumors (P < 0.001) and triple-negative phenotype (P < 0.001). The hazard ratio (HR) for death in patients with PARP-1 overexpressing tumors was 7.24 (95% CI; 3.56-14.75). In a multivariate analysis, PARP-1 overexpression was an independent prognostic factor for both disease-free (HR 10.05; 95% CI 5.42-10.66) and overall survival (HR 1.82; 95% CI 1.32-2.52). CONCLUSIONS Nuclear PARP-1 is overexpressed during the malignant transformation of the breast, particularly in triple-negative tumors, and independently predicts poor prognosis in operable invasive breast cancer.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Animals
- Biomarkers, Tumor/genetics
- Biomarkers, Tumor/metabolism
- Breast Neoplasms/diagnosis
- Breast Neoplasms/metabolism
- Breast Neoplasms/mortality
- Breast Neoplasms/pathology
- Carcinoma, Ductal, Breast/diagnosis
- Carcinoma, Ductal, Breast/metabolism
- Carcinoma, Ductal, Breast/mortality
- Carcinoma, Ductal, Breast/pathology
- Cell Nucleus/metabolism
- Cell Nucleus/pathology
- Cells, Cultured
- Disease Progression
- Embryo, Mammalian
- Female
- Gene Expression Regulation, Neoplastic/drug effects
- Humans
- Mice
- Mice, Knockout
- Middle Aged
- Neoplasm Invasiveness
- Neoplasm Staging
- Poly (ADP-Ribose) Polymerase-1
- Poly(ADP-ribose) Polymerase Inhibitors
- Poly(ADP-ribose) Polymerases/genetics
- Poly(ADP-ribose) Polymerases/metabolism
- Prognosis
- RNA, Small Interfering/pharmacology
- Survival Analysis
- Up-Regulation/drug effects
- Up-Regulation/genetics
Collapse
Affiliation(s)
- F Rojo
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Department of Pathology, Hospital del Mar, Barcelona; Department of Pathology, IIS-Fundación Jiménez Díaz, Madrid
| | - J García-Parra
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Medical Oncology Department, Hospital del Mar, Barcelona
| | - S Zazo
- Department of Pathology, IIS-Fundación Jiménez Díaz, Madrid
| | - I Tusquets
- Medical Oncology Department, Hospital del Mar, Barcelona
| | - J Ferrer-Lozano
- Department of Oncology and Hematology, Hospital Clinico Universitario, Valencia
| | - S Menendez
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Medical Oncology Department, Hospital del Mar, Barcelona
| | - P Eroles
- Department of Oncology and Hematology, Hospital Clinico Universitario, Valencia
| | - C Chamizo
- Department of Pathology, IIS-Fundación Jiménez Díaz, Madrid
| | - S Servitja
- Medical Oncology Department, Hospital del Mar, Barcelona
| | | | - F Lobo
- Department of Oncology, IIS-Fundación Jiménez Díaz, Madrid
| | - B Bellosillo
- Department of Pathology, Hospital del Mar, Barcelona
| | - J M Corominas
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Department of Pathology, Hospital del Mar, Barcelona; Department of Medicine, Autonomous University of Barcelona, Barcelona
| | - J Yelamos
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Immunology Department, Hospital del Mar, Barcelona
| | - S Serrano
- Department of Pathology, Hospital del Mar, Barcelona; Department of Medicine, Autonomous University of Barcelona, Barcelona
| | - A Lluch
- Department of Oncology and Hematology, Hospital Clinico Universitario, Valencia; Department of Medicine, Valencia Central University, Valencia, Spain
| | - A Rovira
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Medical Oncology Department, Hospital del Mar, Barcelona
| | - J Albanell
- Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona; Medical Oncology Department, Hospital del Mar, Barcelona; Department of Medicine, Autonomous University of Barcelona, Barcelona.
| |
Collapse
|
25
|
Chamizo C, Moreno J, Alvar J. Semi-quantitative analysis of cytokine expression in asymptomatic canine leishmaniasis. Vet Immunol Immunopathol 2005; 103:67-75. [PMID: 15626462 DOI: 10.1016/j.vetimm.2004.08.010] [Citation(s) in RCA: 82] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2003] [Revised: 07/05/2004] [Accepted: 08/25/2004] [Indexed: 11/20/2022]
Abstract
The dog is the main reservoir of Leishmania infantum, the parasite responsible for visceral leishmaniasis in Mediterranean countries. The infection in dogs shows different clinical presentations, from subclinical/asymptomatic to a fully developed disease, depending on the host's immune responses. The Th1/Th2 dichotomy is not clear in the different forms of canine leishmaniasis, since the data available from studies of immunity response in canine leishmaniasis are scarce and fragmented. The present work describes the cytokine expression in peripheral blood mononuclear cells (PBMC) obtained from asymptomatic dogs experimentally infected with L. infantum that present a cellular protective immune response. The results obtained from freshly isolated PBMC showed expressions of TNF-alpha, IL-2, IFN-gamma, IL-10 and IL-18 mRNA, similar to those from non-infected dogs. However, there was almost no expression of IL-4 mRNA detected in the asymptomatic infected dogs compared to the control dogs. Unspecific stimulation with ConA promoted the expression in a greater or lower degree of all the cytokines studied. In vitro stimulation of PBMC with soluble leishmanial antigen (SLA) promoted the expression of IL-2, IFN-gamma, TNF-alpha, IL-18, IL-4, IL-6 and IL-10 mRNA, with the two first being specifically induced. Although both Th1 and Th2 cytokines are produced, cell mediated immunity observed in these L. infantum-infected asymptomatic dogs depended on the preferential expression of Th1 cytokines.
Collapse
Affiliation(s)
- Cristina Chamizo
- WHO Collaborating Centre for Leishmaniasis, Parasitology Service, National Centre of Microbiology, Instituto de Salud Carlos III, Madrid, Spain
| | | | | |
Collapse
|
26
|
Chamizo C, Rubio JM, Moreno J, Alvar J. Semi-quantitative analysis of multiple cytokines in canine peripheral blood mononuclear cells by [correction of zby] a single tube RT-PCR. Vet Immunol Immunopathol 2001; 83:191-202. [PMID: 11730929 DOI: 10.1016/s0165-2427(01)00385-3] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Cytokines play an important role in the regulation of the immune system, but low circulating levels in plasma make routine measurement a difficult task. A new methodology based on single tube RT-PCR has been developed to determine the expression of multiple canine cytokines (TNF-alpha, IL-2, IFN-gamma, IL-18, IL-4, IL-6 and IL-10) using primers and protocols designed allow specific amplification of the mRNAs. The technique is performed in one tube in two consecutive steps, a specific transcription of the mRNA of a given cytokine and amplification of the corresponding gene by PCR. The technique was used to analyse the mRNA cytokine profile of peripheral blood mononuclear cells (PBMCs) from healthy dogs using two approaches: (i) analysis of PBMC isolated ex vivo; (ii) analysis of PBMC after in vitro cultures with or without the mitogen ConA. The samples were separated in agarose gels and the intensity of ethidium bromide signals quantified using standard video imaging equipment. Results were interpreted as the ratio of cytokine to GAPDH expression. The results obtained show that the method is easy to use and reproducible. Therefore, this method of monitoring the mRNA cytokine expression might be an useful tool for understanding the immune response in dogs.
Collapse
Affiliation(s)
- C Chamizo
- WHO Collaborating Centre for Leishmaniasis, Servicio de Parasitología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Ctra. Majadahonda-Pozuelo, Km 2, 28220 Majadahonda, Madrid, Spain
| | | | | | | |
Collapse
|
27
|
Moreno J, Cañavate C, Chamizo C, Laguna F, Alvar J. HIV--Leishmania infantum co-infection: humoral and cellular immune responses to the parasite after chemotherapy. Trans R Soc Trop Med Hyg 2000; 94:328-32. [PMID: 10975014 DOI: 10.1016/s0035-9203(00)90345-6] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Specific serum antibodies, peripheral blood T-cell subsets, cellular response in vitro to soluble Leishmania antigens, phenotype of stimulated cells, and serum levels of tumour necrosis factor (TNF)-alpha and transforming growth factor (TGF)-beta 1 were studied in Spain in 17 patients co-infected with HIV and Leishmania infantum who had been previously treated with pentavalent antimony. Both humoral and cellular responses to Leishmania sp. appeared diminished, 8 out of 17 patients were positive by indirect immunofluorescence, and immunoblotting detected heterogeneous antibody-binding pattern in 11 out of 13 subjects. A blastogenesis test was positive in 4 cases; 2 of them presented proliferation of CD4+ cells while CD8+ cells proliferated in the other 2 patients. Serum levels of TNF-alpha were similar to those observed in patients infected with HIV only, while serum levels of TGF-beta 1 were significantly lower in the co-infected patients. The inability of antibody response to control the parasite and the absence of specific T-cell immunity to Leishmania sp. would explain the high frequency of relapses reported in these patients. The decreased levels of TGF-beta 1 could have an important role in the interaction between the 2 pathogens.
Collapse
Affiliation(s)
- J Moreno
- WHO Collaborating Centre for Leishmaniasis, Research Unit in Tropical Medicine and International Health (FIS-ISCIII), Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
| | | | | | | | | |
Collapse
|
28
|
Moreno J, Nieto J, Chamizo C, González F, Blanco F, Barker DC, Alvar J. The immune response and PBMC subsets in canine visceral leishmaniasis before, and after, chemotherapy. Vet Immunol Immunopathol 1999; 71:181-95. [PMID: 10587300 DOI: 10.1016/s0165-2427(99)00096-3] [Citation(s) in RCA: 73] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Peripheral blood mononuclear cell subsets, in vitro lymphoproliferative response to leishmanial antigen, and Leishmania-specific serum antibody levels were examined in 11 dogs, naturally infected with L. infantum, and 9 healthy control dogs. A decrease in the percentage of CD4+ T-cells and an increase in the proportion of gammadelta T-cells and sIgG+ B-cells were observed during canine visceral leishmaniasis (CVL). These changes may be responsible for the marked humoral response and the absence of in vitro lymphoproliferation to mitogen and specific parasite antigens. This possibility was supported by the analysis of these subsets after treatment with amphotericin B. One month after therapy, a significant increase in the percentage of CD4+ T-cells and a decrease of gammadelta T-cells and sIgG+ B-cells were observed. At the same time, the lymphocyte blastogenesis assay with leishmanial antigen was positive and the levels of specific antibodies to Leishmania were significantly lower than before the treatment. Five months after therapy, lymphocyte proliferative response to LSA disappeared, antibody and lymphocyte subsets levels returned to those observed during CVL. Therapeutic failure in CVL is associated with the inability of antileishmanial drugs to completely revert the profound immunodepression induced by the infection and prevent relapse.
Collapse
Affiliation(s)
- J Moreno
- WHO Collaborating Centre for Leishmaniasis, Research Unit for Tropical Diseases and International Health, Centro Nacional de Microbiología, Instituto de Carlos III, Ctra. Majadahonda-Pozuelo, Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
29
|
Abstract
The objective of this study was to ascertain the prevalence and incidence of Multiple Sclerosis (MS) in a population of 33,775 in two primary health care centres in the sanitary district of Gijon, Asturias, northern Spain. Many information sources were used but the unique advantage of Gijon was that the city has a centralized computerized register of all diagnoses made for all consultations in the clinics and hospitals in the area. The HLA distribution in the population was already known and the Poser classification of MS was used. The crude MS prevalence was 65/100,000, a similar prevalence to that found in southern and eastern Spain, Sicily and Greek-speaking Cyprus. The mean incidence was 3.7/100,000 per year. The study demonstrated the advantage of a centralized and computerized medical recording system and demonstrates that northern Spain is a moderately high or medium MS risk zone.
Collapse
Affiliation(s)
- D F Uria
- Hospital San Agustin, Aviles, Department of Neurology, Asturias, Spain
| | | | | | | | | | | | | |
Collapse
|
30
|
|
31
|
Espinosa-Urgel M, Chamizo C, Tormo A. Sigma s regulates pLS1 maintenance in stationary-phase Escherichia coli. FEMS Microbiol Lett 1996; 135:45-50. [PMID: 8598276 DOI: 10.1111/j.1574-6968.1996.tb07964.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
We have studied the influence of sigma s on the stability and number of copies of the promiscuous plasmid pLS1 in Escherichia coli. Our results indicate that pLS1 is less stable and has a lower number of copies in a rpoS mutant than in a wild-type strain during stationary phase. This behaviour does not seem to be due to differences in the expression of pLS1 replication regulators, but to be related to plasmid topology.
Collapse
Affiliation(s)
- M Espinosa-Urgel
- Departamento de Bioquímica y Biología Molecular I, Facultad de Ciencias Biológicas, Universidad Complutense, Madrid, Spain
| | | | | |
Collapse
|